Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: Characterization of resistant cells

International Journal of Oncology

Volumn 37, Issue 2, 2010, Pages 307-315

  Zheng, Xuqin ^a   Cui, Dai ^a,c   Xu, Shuhang ^a   Brabant, Georg ^b   Derwahl, Michael ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cancer stem cells; Doxorubicin; Resistance; Sphere formation; Thyroid

Indexed keywords

ABC TRANSPORTER; BETA ACTIN; BREAST CANCER RESISTANCE PROTEIN; DOXORUBICIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; OCTAMER TRANSCRIPTION FACTOR 4; ANTINEOPLASTIC ANTIBIOTIC; INDOLE DERIVATIVE; POU5F1 PROTEIN, HUMAN; TRYPTOQUIVALINE; TUMOR MARKER; VERAPAMIL;

ANAPLASTIC CARCINOMA; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER STEM CELL; CELL POPULATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA; TREATMENT OUTCOME; UPREGULATION; CARCINOMA; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; PHYSIOLOGY; THYROID TUMOR; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; SPHEROIDS, CELLULAR; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VERAPAMIL;

EID: 77954148544     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000679     Document Type: Article

References (30)

1. Are C and Shaha AR: Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13: 453-464, 2006.
2. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY and Clark OH: Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91: 2335-2342, 2001.
3. Jordan CT, Guzman ML and Noble M: Cancer stem cells. N Engl J Med 355: 1253-1261, 2006.
4. Ward RJ and Dirks PB: Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol 2: 175-189, 2007. (Pubitemid 46448063)
5. Kondo T, Setoguchi T and Taga T: Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 101: 781-786, 2004.
6. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA and Brenner MK: A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101: 14228-14233, 2004.
7. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J and Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828, 2003.
8. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M and Kornblum HI: Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100: 15178-15183, 2003.
9. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD and Steindler DA: Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39: 193-206, 2002.
10. Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737, 1997.
11. + anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin. PLoS One 4: e5395, 2009.
12. Zito G, Richiusa P, Bommarito A, Carissimi E, Russo L, Coppola A, Zerilli M, Rodolico V, Criscimanna A, Amato M, Pizzolanti G, Galluzzo A and Giordano C: In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One 3: e3544, 2008.
13. Thomas D, Friedman S and Lin RY: Thyroid stem cells: lessons from normal development and thyroid cancer. Endocr Relat Cancer 15: 51-58, 2008.
14. Thomas T, Nowka K, Lan L and Derwahl M: Expression of endoderm stem cell markers: evidence for the presence of adult stem cells in human thyroid glands. Thyroid 16: 537-544, 2006.
15. Lan L, Cui D, Nowka K and Derwahl M: Stem cells derived from goiters in adults form spheres in response to intense growth stimulation and require thyrotropin for differentiation into thyrocytes. J Clin Endocrinol Metab 92: 3681-3688, 2007. (Pubitemid 47435356)
16. Fierabracci A, Puglisi MA, Giuliani L, Mattarocci S and Gallinella-Muzi M: Identification of an adult stem/progenitor cell-like population in the human thyroid. J Endocrinol 198: 471-487, 2008.
17. Takano T and Amino N: Fetal cell carcinogenesis: a new hypothesis for better understanding of thyroid carcinoma. Thyroid 15: 432-438, 2005. (Pubitemid 40770622)
18. Mitsutake N, Iwao A, Nagai K, Namba H, Ohtsuru A, Saenko V and Yamashita S: Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology 148: 1797-1803, 2007. (Pubitemid 46457095)
19. Goodell MA, Brose K, Paradis G, Conner AS and Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183: 1797-1806, 1996.
20. Broecker M, Hammer J and Derwahl M: Excessive activation of tyrosine kinases leads to inhibition of proliferation in a thyroid carcinoma cell line. Life Sci 63: 2373-2386, 1998.
21. Niwa H, Miyazaki J and Smith AG: Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24: 372-376, 2000.
22. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H and Sorrentino BP: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7: 1028-1034, 2001.
23. Li L and Neaves WB: Normal stem cells and cancer stem cells: the niche matters. Cancer Res 66: 4553-4557, 2006.
24. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
25. Feuring-Buske M and Hogge DE: Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemia. Blood 97: 3882-3889, 2001.
26. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK and Trosko JE: Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 26: 495-502, 2005.
27. Gidekel S, Pizov G, Bergman Y and Pikarsky E: Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 4: 361-370, 2003.
28. Duan Z, Choy E, Jimeno JM, Cuevas CD, Mankin HJ and Hornicek FJ: Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines. Cancer Chemother Pharmacol (In press).
29. Asakawa H, Kobayashi T, Komoike Y, Yanagawa T, Takahashi M, Wakasugi E, Maruyama H, Tamaki Y, Matsuzawa Y and Monden M: Establishment of anaplastic thyroid carcinoma cell lines useful for analysis of chemosensitivity and carcinogenesis. J Clin Endocrinol Metab 81: 3547-3552, 1996.
30. Van Staveren WC, Solis DW, Delys L, Duprez L, Andry G, Franc B, Thomas G, Libert F, Dumont JE, Detours V and Maenhaut C: Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. Cancer Res 67: 8113-8120, 2007.